Cost-utilities Analysis of Polatuzumab Vedotin Combined with Bendamustine and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma Which Is Unsuited for Hematopoietic Stem Cell Transplantation
DOI:
https://doi.org/10.54097/fbem.v8i3.7835Keywords:
Polatuzumab Vedotin (Polivy), Relapsed/Refractory diffuse large b-cell lymphoma, Pharmacoeconomic analysis.Abstract
Objectives To evaluate the cost-utilities of Polatuzumab Vedotin (Polivy) combined with bendamustine and rituximab regimen (BR) for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) which is unsuited for hematopoietic stem cell transplantation. Methods From the perspective of the China 's health system, the cost-utilities analysis of BR regimen combined with Polatuzumab Vedotin (Polivy) and BR regimen alone for relapsed/refractory DLBCL which is unsuited for hematopoietic stem cell transplantation was analyzed by using partitioned survival model (PSM). Results Compared with BR regimen alone, BR regimen combined with Polatuzumab Vedotin (Polivy) for relapsed/refractory DLBCL which is unsuited for hematopoietic stem cell transplantation patients can increase 1.1706 QALYs in 15 years, the total cost is increased by 231 117.9 yuan, and the ICUR value is 197 434.7 yuan/QALY. The sensitivity analysis confirmed the robustness of the results. Conclusion In the long run, compared with BR alone, BR combined with Polatuzumab Vedotin (Polivy) doesn’t have cost-effectiveness advantages for relapsed/refractory DLBCL which is unsuited for hematopoietic stem cell transplantation patients.
Downloads
References
Chinese Anti-Cancer Association Lymphoma Professional Committee. Chinese lymphoma treatment guidelines ( 2021 edition ) [J]. Chinese journal of oncology,2021,7:707-735.
Sehn LH, Salles G. Diffuse large B-cell lymphoma. 2021[J]. N Engl J Med, 2021,384(9):842-858.
Sarkozy C, Sehn LH. Management of relapsed/refractory DLBCL. 2018[J]. Best Pract Res Clin Haematol, 2018,31(3):209-216.
Laurie HS, Mark H, Stephen O, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/ refractory DLBCL: survival update and new extension cohort data. 2022[J]. Blood Advances, 2022,6(2): 533-543.
Liu Guoen. Chinese Pharmacoeconomic Evaluation Guide 2020 [M]. Beijing: China Market Publisher, 2020:4-16.
Yao Jiaqi, Guan Xin, Zhang Yao, et al. Discussion and Practice of Correlating Parameters in Sensitivity Analysis of Pharmacoeconomics [J]. Chinese journal of Drug Evaluation, 2019, 36(2): 150-155.
Shao Rongjie, Tang Wenxi, Ma Aixia. Application of partition survival model in pharmacoeconomic evaluation [J]. Chinese Health Economics, 2019, 38(9): 60-63.
Shi Fenghao, Shang Ye, Rui Mingjun, et al. Application of R language “survHE” package in health economics evaluation [J]. Chinese Health Economics, 2020, 39(9): 9-14.
Jia Shihuan, Zhao Mengmeng, Chen Binbin, et al. Pharmacoeconomic Evaluation of Rituximab (Hanlikang) Combined with Chop Chemotherapy Regimen for Diffuse Large B-cell Lymphoma [J]. China Journal of Pharmaceutical Economics, 2019, 14(10): 20-27.
Mingjun Rui, Zhengyang Fei, Yingcheng Wang, et al. Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China[J]. Journal of Medical Economics, 2022, 25(1): 618-629.
National Bureau of Statistics. 2022 Statistical Bulletin of the People 's Republic of China on National Economic and Social Development [EB/OL]. (2023-02-28) [2023-03-31]. http://www.stats.gov.cn/sj/zxfb/202302/t20230228_1919011.html.
Yuqin Song, Herve Tilly, Shinya Rai, et al. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the Phase 3 POLARIX trial[J].Blood, 2023, 141(2): 130-166.
Sun Lei, Zhou Dachuang, Chen Pingyu, et al. Pharmacoeconomic evaluation of ensatinib in the first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer [J]. China Pharmacy, 2022, 33(12): 1479-1484.
Downloads
Published
Issue
Section
How to Cite
